The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...
The Jordan Times on MSN5h
Hikma Pharmaceuticals reports 'strong' 2024 results with 9% revenue growthAMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 ...
In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Hosted on MSN18h
Takeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
SAN JOSE, CA, USA I5, 2025 I BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally “hard-to-drug” targets, announced today a strategic collaboration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback